Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.61 |
| ▸ | CDK2 | P24941 | 19/20 | 0.61 |
| ▸ | CCND1 | P24385 | 14/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.61 |
| ▸ | CDK4 | P11802 | 7/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.61 |
| ▸ | CDK9 | P50750 | 6/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868160 | 0.90 | CDK2 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868272 | 0.89 | CDK2 (0.59) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868153 | 0.89 | CDK2 (0.61) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868271 | 0.88 | MAPK8 (0.53) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL17910154 | 0.85 | MAPK8 (0.60) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868274 | 0.85 | CDK2 (0.54) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868282 | 0.85 | CDK2 (0.54) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868310 | 0.84 | CDK2 (0.55) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868304 | 0.83 | CDK2 (0.65) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868164 | 0.83 | CDK2 (0.58) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 28/4885CDK2 1/4885CCND1 39/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CCNE1 40/4885CDK2 6/4885CCND1 45/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.